US · MLAB · MEDICAL - EQUIPMENT & SERVICES
Mesa Laboratories, Inc. (MLAB) intrinsic value and stock valuation
$127.93as of 2026-11-21 · Mkt cap 574.25M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Mesa Laboratories, Inc. DCF and intrinsic value
InvestorsCraft values MLAB with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from MLAB’s statements →
Mesa Laboratories, Inc. Graham Number
Graham Number: $30.41d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2012–2026, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $249.1M | $241M | $216.2M | $219.1M | $184.3M |
| Operating income | $18.5M | $16.3M | -$-272.07M | $3.32M | $4.7M |
| Net income | $6.71M | -$-1.97M | -$-254.25M | $930K | $1.87M |
| EPSd | $1.2M | -$-362.8K | -$-47.17M | $173.5K | $350.8K |
| Operating cash flow | $42.8M | $46.8M | $44.1M | $28M | $39.2M |
| Capital expenditure | -$-3.25M | -$-4.5M | -$-2.57M | -$-4.54M | -$-4.43M |
| Free cash flow | $39.6M | $42.3M | $41.6M | $23.4M | $34.8M |
| Total assets | $427.8M | $433.4M | $446.8M | $661.8M | $707.4M |
| Total debt | $168.8M | $181.5M | $231.3M | $186.1M | $221.1M |
| Net debt | $141.9M | $154.2M | $203.1M | $153.2M | $171.8M |
| Total equity | $186.3M | $159.8M | $145.4M | $393.5M | $393.8M |
| Cash and short-term investments | $26.9M | $27.3M | $28.2M | $32.9M | $49.4M |
Income statement
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $249.1M | $241M | $216.2M | $219.1M | $184.3M |
| Cost of revenue | $90.9M | $90.1M | $82.9M | $85.4M | $75.3M |
| Gross profit | $158.3M | $150.9M | $133.3M | $133.7M | $109.1M |
| Research and development expenses | $20.3M | $19.5M | $19.3M | $20.5M | $15.8M |
| Selling, general and administrative expenses | $119.5M | $115M | $111.5M | $109.9M | $88.6M |
| Other expenses | $0.00 | $0.00 | $274.5M | $0.00 | $0.00 |
| Operating expenses | $139.8M | $134.5M | $405.3M | $130.4M | $104.4M |
| Cost and expenses | $230.6M | $224.6M | $488.3M | $215.8M | $179.6M |
| Interest income | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $10.7M | $11.9M | $5.7M | $4.77M | $3.88M |
| Depreciation and amortization | $23.3M | $24.5M | $31.6M | $33.1M | $25.1M |
| Ebitda | $35.3M | $42.4M | -$-238.38M | $37.5M | $32.5M |
| Operating income | $18.5M | $16.3M | -$-272.07M | $3.32M | $4.7M |
| Total other income/expenses, net | -$-6.5M | -$-10.38M | -$-3.57M | -$-3.71M | -$-1.13M |
| Income before tax | $12M | $5.96M | -$-275.65M | -$-390K | $3.57M |
| Income tax expense | $5.3M | $7.93M | -$-21.4M | -$-1.32M | $1.7M |
| Net income | $6.71M | -$-1.97M | -$-254.25M | $930K | $1.87M |
| Weighted average shares outstanding | $5.51M | $5.43M | $5.39M | $5.32M | $5.21M |
| Weighted average diluted shares outstanding | $5.57M | $5.43M | $5.39M | $5.36M | $5.33M |
Balance sheet
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $26.9M | $27.3M | $28.2M | $32.9M | $49.4M |
| Net receivables | $44.1M | $42M | $39.1M | $42.6M | $41.2M |
| Inventory | $26.4M | $25.4M | $32.7M | $34.6M | $24.6M |
| Total current assets | $106.3M | $102.7M | $109.4M | $119M | $124.3M |
| Property, plant and equipment, net | $48.1M | $32.3M | $41.4M | $28.2M | $28.6M |
| Goodwill and intangible assets | $270.2M | $278.6M | $293.9M | $503.3M | $541.3M |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $321.5M | $330.7M | $337.4M | $542.9M | $583.1M |
| Total assets | $427.8M | $433.4M | $446.8M | $661.8M | $707.4M |
| Accounts payable | $4.93M | $5.75M | $6.04M | $6.13M | $7.9M |
| Short-term debt | $9.31M | $104.6M | $2.99M | $2.87M | $2.77M |
| Deferred revenue | $14.7M | $14.7M | $15.5M | $15.7M | $14.6M |
| Total current liabilities | $61.9M | $164M | $44.3M | $43.4M | $48.1M |
| Long-term debt | $159.5M | $76.9M | $228.3M | $183.3M | $218.4M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $179.6M | $109.6M | $257.1M | $225M | $265.5M |
| Capital lease obligations | $17.4M | $3.52M | $9.6M | $2.87M | $2.77M |
| Total liabilities | $241.5M | $273.5M | $301.4M | $268.4M | $313.6M |
| Common stock | $375.4M | $358.5M | $343.6M | $332.1M | $313.5M |
| Retained earnings | -$-185.75M | -$-188.94M | -$-183.49M | $74.2M | $76.7M |
| Accumulated other comprehensive income (loss) | -$-3.36M | -$-9.78M | -$-14.76M | -$-12.79M | $3.67M |
| Total equity | $186.3M | $159.8M | $145.4M | $393.5M | $393.8M |
| Total investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $168.8M | $181.5M | $231.3M | $186.1M | $221.1M |
| Net debt | $141.9M | $154.2M | $203.1M | $153.2M | $171.8M |
Cash flow statement
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Net income | $6.71M | -$-1.97M | -$-254.25M | $930K | $1.87M |
| Depreciation and amortization | $23.3M | $24.5M | $31.6M | $33.1M | $25.1M |
| Stock-based compensation | $17.9M | $13.1M | $11.9M | $12.5M | $11.4M |
| Change in working capital | -$-4.99M | $6.9M | $5.97M | -$-17.11M | -$-7.19M |
| Accounts receivable | -$-3.21M | -$-2.92M | $4.94M | -$-2.12M | -$-6.75M |
| Inventory | -$-4.43M | $1.15M | $2.56M | -$-10.18M | -$-1.04M |
| Accounts payable | -$-1.2M | -$-390K | -$-100K | -$-1.54M | $1.37M |
| Net cash provided by operating activities | $42.8M | $46.8M | $44.1M | $28M | $39.2M |
| Investments in property, plant and equipment | -$-3.25M | -$-4.25M | -$-2.57M | -$-4.54M | -$-4.43M |
| Acquisitions, net | $0.00 | $0.00 | -$-78.74M | -$-4.95M | -$-300.79M |
| Net cash used for investing activities | -$-3.25M | -$-4.5M | -$-81.31M | -$-9.49M | -$-305.23M |
| Common stock issued | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | -$-3.52M | -$-3.47M | -$-3.45M | -$-3.41M | -$-3.34M |
| Net cash used for financing activities | -$-41.85M | -$-44.51M | $32.8M | -$-33.33M | $52.6M |
| Net change in cash | -$-390K | -$-890K | -$-4.7M | -$-16.44M | -$-214.52M |
| Cash at end of period | $26.9M | $27.3M | $28.2M | $32.9M | $49.4M |
| Operating cash flow | $42.8M | $46.8M | $44.1M | $28M | $39.2M |
| Capital expenditure | -$-3.25M | -$-4.5M | -$-2.57M | -$-4.54M | -$-4.43M |
| Free cash flow | $39.6M | $42.3M | $41.6M | $23.4M | $34.8M |
Line items
Line items
Line items
About Mesa Laboratories, Inc.
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment’s products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.
- CEO
- Siddhartha C. Kadia
- Employees
- 717
- Beta
- 0.93
Included in
Explore
Frequently asked questions
What is the intrinsic value of Mesa Laboratories, Inc. (MLAB)?
Mesa Laboratories, Inc. (MLAB) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is MLAB undervalued?
MLAB trades at a price of $127.93 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.